Sesen's PhI­II blad­der can­cer da­ta send stock south as in­vestors fret over safe­ty

Fol­low­ing a brand­ing makeover just last week, Sesen Bio (which used to go by Eleven Bio­ther­a­peu­tics) has pub­lished three-month da­ta for its blad­der can­cer drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER